Extended Data Fig. 7: mAb Z10 promotes phagocytosis with SIRPα blockade.
From: CD47 masks pro-phagocytic ligands in cis on tumor cells to suppress antitumor immunity
a,b, Phagocytosis assay of Daudi (a, left), MM.1 S (a, right), and Fc-silent CD3 + CD28 mAbs activated mouse CD8+ T cells expressing (b, right) or not expressing (b, left) hSLAMF7 by WT or Sirpa-/- BMDMs assayed by fluorescence microscopy. c, Schematic representations of the impact of mAb Z10 on macrophages or target cells. d, Tumors from experiment depicted in Fig. 6g were dissected, weighed, measured, and analysed by flow cytometry. One mouse showed no detectable tumor in the ‘SIRPα mAb (#27) + SLAMF7 mAb (Z10)’ group on day 24. All data are means ± s.e.m. ns, not significant; **p < 0.01, ***p < 0.001, and ****p < 0.0001. Results are pooled from 3 (a,b) mice studied in 3 (a,b) independent experiments; 8 [except 7 for ‘SLAMF7 mAb (Z10)’ and ‘SIRPα mAb (#27)’ groups] mice from 2 independent experiments (d). Each symbol represents one mouse.
